OLUMIANT® is a Janus kinase (JAK) inhibitor indicated for:

- the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. (1.1)

**CONTRAINDICATIONS**

None.

**WARNINGS AND PRECAUTIONS**

- Gastrointestinal Perforations: Monitor patients who may be at increased risk and evaluate promptly new onset of abdominal symptoms. (5.6)
- Laboratory Abnormalities: Monitor for changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids. (5.7)
- Vaccinations: Avoid use with live vaccines. (5.8)
- Hypersensitivity: Serious reactions have been reported. (5.9)

**ADVERSE REACTIONS**

Adverse reactions (≥1%) are:
- **Rheumatoid Arthritis:** upper respiratory tract infections, nausea, herpes simplex, and herpes zoster. (6.1)
- **COVID-19:** increases of liver enzymes, thrombocytosis, creatine phosphokinase increases, neutropenia, deep vein thrombosis, pulmonary embolism, and urinary tract infection (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**DRUG INTERACTIONS**

In patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (e.g., probenecid) the recommended dosage should be reduced (2.6, 7.1)

**USE IN SPECIFIC POPULATIONS**

- **Hepatic Impairment:** OLUMIANT is not recommended in patients with hepatic impairment. OLUMIANT has not been studied in patients with eGFR <15 mL/min/1.73m². (2.5, 8.6)
- **Renal Impairment:** OLUMIANT is not recommended in COVID-19 patients with eGFR <15 mL/min/1.73m², who are on dialysis, have ESRD, or acute kidney injury. OLUMIANT is not recommend in patients with rheumatoid arthritis patients with eGFR >30 mL/min/1.73m². (2.5, 8.7).

**DOSE FORMS AND STRENGTHS**

Tablets: 4 mg, 2 mg, 1 mg (3)

**DOSAGE AND ADMINISTRATION**

Recommended Dosage:

- **Rheumatoid Arthritis:**
  - Recommended dosage is 2 mg once daily. (2.2)
  - OLUMIANT may be used as monotherapy or in combination with methotrexate or other DMARDs. (2.2)

- **COVID-19:**
  - Recommended dosage is 4 mg once daily for up to 14 days. (2.3)

Dosage Modifications in Patients with Renal or Hepatic Impairment, or Cytopenias:

- See the full prescribing information for dosage modifications by indication for patients with renal or hepatic impairment; and patients with lymphopenia, neutropenia, or anemia (2.4, 5.7)

**INDICATIONS AND USAGE**

OLUMIANT® is a Janus kinase (JAK) inhibitor indicated for:

- the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. (1.1)
FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis
1.2 Coronavirus Disease 2019 (COVID-19)

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation
2.2 Dosage Recommendations in Rheumatoid Arthritis
2.3 Dosage Recommendations in COVID-19
2.4 Dosage Modifications Due to Infections, Cytopenias and Anemia
2.5 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment
2.6 Dosage Modifications Due to Drug Interactions
2.7 Alternative Administration for Patients Unable to Swallow Tablets

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections
5.2 Mortality
5.3 Malignancy and Lymphoproliferative Disorders
5.4 Major Adverse Cardiovascular Events
5.5 Thrombosis
5.6 Gastrointestinal Perforations
5.7 Laboratory Abnormalities
5.8 Vaccinations
5.9 Hypersensitivity

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience
6.2 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Strong OAT3 Inhibitors
7.2 Other JAK Inhibitors or Biologic DMARDs

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Hepatic Impairment
8.7 Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis
14.2 COVID-19

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied
16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS

SERIOUS INFECTIONS
Patients treated with OLUMIANT are at risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

If a serious infection develops, interrupt OLUMIANT until the infection is controlled.

Reported infections include:
- Active tuberculosis, which may present with pulmonary or extrapulmonary disease. OLUMIANT should not be given to patients with active tuberculosis. Patients, except those with COVID-19, should be tested for latent tuberculosis before initiating OLUMIANT and during therapy. If positive, start treatment for latent infection prior to OLUMIANT use.
- Invasive fungal infections, including candidiasis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
- Bacterial, viral, and other infections due to opportunistic pathogens.

The risks and benefits of treatment with OLUMIANT should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with OLUMIANT including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (5.1)].

MORTALITY
In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions (5.2)].

MALIGNANCIES
Lymphoma and other malignancies have been observed in patients treated with OLUMIANT. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3)].

MAJOR ADVERSE CARDIOVASCULAR EVENTS
In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions (5.4)].

THROMBOSIS
Thrombosis, including deep venous thrombosis and pulmonary embolism, has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid OLUMIANT in patients at risk. Patients with symptoms of thrombosis should discontinue OLUMIANT and be promptly evaluated. [see Warnings and Precautions (5.5)].
OLUMIANT® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.

Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

1.2 Coronavirus Disease 2019 (COVID-19)
OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation
Prior to OLUMIANT treatment initiation, consider performing the following evaluations:

- Active and latent tuberculosis (TB) infection evaluation – OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with rheumatoid arthritis, consider treatment for TB prior to OLUMIANT use [see Warnings and Precautions (5.1)].
- Viral hepatitis screening in accordance with clinical guidelines [see Warnings and Precautions (5.1)].
- Complete blood count – Assess baseline values and verify whether treatment can be initiated:
  - In patients with rheumatoid arthritis, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/µL, absolute neutrophil count (ANC) <1000 cells/µL, or hemoglobin level <8 g/dL.
  - In patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/µL or if the ANC is <500 cells/µL.
- Monitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.4) and Warnings and Precautions (5.7)].
- Baseline hepatic and renal function – Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].

In patients with rheumatoid arthritis, update immunizations in agreement with current immunization guidelines [see Warnings and Precautions (5.8)].

2.2 Dosage Recommendations in Rheumatoid Arthritis
The recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food [see Clinical Pharmacology (12.3)]. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.7)]. OLUMIANT may be used as monotherapy or in combination with methotrexate or other DMARDs.

2.3 Dosage Recommendations in COVID-19
The recommended dosage of OLUMIANT for adults is 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.7)].

2.4 Dosage Modifications Due to Infections, Cytopenias and Anemia

Rheumatoid Arthritis
- Avoid use of OLUMIANT in patients with active, serious infection, including localized infections. If a patient develops a serious infection hold treatment with OLUMIANT until the infection is controlled [see Warnings and Precautions (5.1)].
- Dosage modifications for patients with rheumatoid arthritis and cytopenias or anemia are described in Table 1.

<table>
<thead>
<tr>
<th>Laboratory Analyte</th>
<th>Laboratory Analyte Value</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute Lymphocyte Count (ALC)</td>
<td>≥500 cells/µL</td>
<td>Maintain dosage</td>
</tr>
<tr>
<td></td>
<td>&lt;500 cells/µL</td>
<td>Interrupt OLUMIANT until ALC ≥500 cells/µL</td>
</tr>
<tr>
<td>Absolute Neutrophil Count (ANC)</td>
<td>≥1000 cells/µL</td>
<td>Maintain dosage</td>
</tr>
<tr>
<td></td>
<td>&lt;1000 cells/µL</td>
<td>Interrupt OLUMIANT until ANC ≥1000 cells/µL</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>≥8 g/dL</td>
<td>Maintain dosage</td>
</tr>
</tbody>
</table>

Reference ID: 4981738
COVID-19
- Monitor patients for signs and symptoms of new infections during treatment with OLUMIANT. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered [see Warnings and Precautions (5.1)].
- Dosage modifications for patients with COVID-19 and cytopenias are described in Table 2.

Table 2: Dosage Modifications for Cytopenias in Patients with COVID-19

<table>
<thead>
<tr>
<th>Laboratory Analyte</th>
<th>Laboratory Analyte Value</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute Lymphocyte Count (ALC)</td>
<td>≥200 cells/µL</td>
<td>Maintain dosage</td>
</tr>
<tr>
<td></td>
<td>&lt;200 cells/µL</td>
<td>Interrupt OLUMIANT until ALC ≥200 cells/µL</td>
</tr>
<tr>
<td>Absolute Neutrophil Count (ANC)</td>
<td>≥500 cells/µL</td>
<td>Maintain dosage</td>
</tr>
<tr>
<td></td>
<td>&lt;500 cells/µL</td>
<td>Interrupt OLUMIANT until ANC ≥500 cells/µL</td>
</tr>
</tbody>
</table>

2.5 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment

Rheumatoid Arthritis

Renal Impairment
Dosage modifications for patients with rheumatoid arthritis and renal impairment are described in Table 3.

Table 3: Dosage Modifications for Patients with Rheumatoid Arthritis and Renal Impairment

<table>
<thead>
<tr>
<th>Renal Impairment Stage</th>
<th>Estimated Glomerular Filtration Rate (eGFR)</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>60 – &lt;90 mL/minute/1.73 m²</td>
<td>2 mg once daily</td>
</tr>
<tr>
<td>Moderate</td>
<td>30 - &lt;60 mL/min/1.73 m²</td>
<td>1 mg once daily</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt;30 mL/minute/1.73 m²</td>
<td>Not recommended</td>
</tr>
</tbody>
</table>

Hepatic Impairment
- OLUMIANT is not recommended for use in patients with severe hepatic impairment.
- Interrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.7)].

COVID-19

Renal Impairment
- Dosage modifications for patients with COVID-19 and renal impairment are described in Table 4.
- OLUMIANT is not recommended for use in patients who are on dialysis, have end-stage renal disease (ESRD), or acute kidney injury (eGFR <15 mL/min/1.73 m²).

Table 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment

<table>
<thead>
<tr>
<th>Renal Impairment Stage</th>
<th>Estimated Glomerular Filtration Rate (eGFR)</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>60 - &lt;90 mL/min/1.73 m²</td>
<td>4 mg once daily</td>
</tr>
<tr>
<td>Moderate</td>
<td>30 - &lt;60 mL/min/1.73 m²</td>
<td>2 mg once daily</td>
</tr>
<tr>
<td>Severe</td>
<td>15 - &lt;30 mL/min/1.73 m²</td>
<td>1 mg once daily</td>
</tr>
<tr>
<td>End Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury</td>
<td>&lt;15 mL/min/1.73 m²</td>
<td>Not recommended</td>
</tr>
</tbody>
</table>

Hepatic Impairment
• It is not known if dosage adjustment is needed in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.
• Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.7)].

2.6 Dosage Modifications Due to Drug Interactions

Rheumatoid Arthritis
The recommended dosage of OLUMIANT in patients with rheumatoid arthritis taking strong Organic Anion Transporter 3 (OAT3) inhibitors, such as probenecid, is 1 mg once daily [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

COVID-19
The recommended dosages of OLUMIANT in patients with COVID-19 taking strong OAT3 inhibitors, such as probenecid, are shown in Table 5 [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]:

Table 5: Dosage Modifications when Coadministered with Strong OAT3 Inhibitors in Patients With COVID-19

<table>
<thead>
<tr>
<th>Concomitant Medication</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong OAT3 inhibitors (e.g., probenecid)</td>
<td>If the recommended dosage is 4 mg once daily, reduce to 2 mg once daily.</td>
</tr>
<tr>
<td></td>
<td>If the recommended dosage is 2 mg once daily, reduce dose to 1 mg once daily.</td>
</tr>
<tr>
<td></td>
<td>If the recommended dosage is 1 mg once daily, consider discontinuing probenecid.</td>
</tr>
</tbody>
</table>

2.7 Alternative Administration for Patients Unable to Swallow Tablets
For patients who are unable to swallow whole tablets, an alternative mode of administration may be considered:
• Oral dispersion
• Gastrostomy tube (G tube)
• Nasogastric tube (NG tube) or orogastric tube (OG tube)

Intact tablets are not hazardous. Tablets may be crushed to facilitate dispersion. It is not known if powder from the crushed tablets may constitute a reproductive hazard to the preparer. If tablets are crushed, use proper control measures (e.g., ventilated enclosure) or personal protective equipment (i.e., N95 respirator). Dispersed tablets are stable in water for up to 4 hours.

Preparation Instructions for Alternative Administration:

• **Oral administration of dispersed tablets in water:** For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally. The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient (Table 6).

• **Administration via G tube:** For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 6).

• **Administration via NG or OG tube:** For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 6).
Table 6: Dispersion and Rinse Volume for Alternative Administration

<table>
<thead>
<tr>
<th>Administration via</th>
<th>Dispersion Volume</th>
<th>Container Rinse Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral dispersion</td>
<td>10 mL</td>
<td>10 mL</td>
</tr>
<tr>
<td>G tube</td>
<td>15 mL</td>
<td>15 mL</td>
</tr>
<tr>
<td>NG tube or OG tube</td>
<td>30 mL</td>
<td>15 mL</td>
</tr>
</tbody>
</table>

3 DOSAGE FORMS AND STRENGTHS
OLUMIANT is available as debossed, film-coated tablets:
- 1 mg tablet contains a recessed area on each face of the tablet surface, is very light pink, round, debossed with “Lilly” on one side and “1” on the other.
- 2 mg tablet contains a recessed area on each face of the tablet surface, is light pink, oblong, debossed with “Lilly” on one side and “2” on the other.
- 4 mg tablet contains a recessed area on each face of the tablet surface, is medium pink, round, debossed with “Lilly” on one side and “4” on the other.

4 CONTRAINDICATIONS
None.

5 WARNINGS AND PRECAUTIONS
5.1 Serious Infections
Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients with rheumatoid arthritis receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection [see Adverse Reactions (6.1)]. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Avoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients:
- with chronic or recurrent infection
- who have been exposed to tuberculosis
- with a history of a serious or an opportunistic infection
- who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or
- with underlying conditions that may predispose them to infection.

In patients with rheumatoid arthritis, closely monitor for the development of signs and symptoms of infection during and after treatment with OLUMIANT. Interrupt OLUMIANT in patients with rheumatoid arthritis, if the patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and OLUMIANT should be interrupted if the patient is not responding to therapy. Do not resume OLUMIANT until the infection is controlled.

In patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with OLUMIANT. There is limited information regarding the use of OLUMIANT in patients with COVID-19 and concomitant active serious infections. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered.

Tuberculosis
Evaluate patients for active infection prior to administration of OLUMIANT. OLUMIANT should not be given to patients with active TB.

Test patients with rheumatoid arthritis for latent tuberculosis. Patients with rheumatoid arthritis and latent tuberculosis (TB) should be treated with standard antimycobacterial therapy before initiating OLUMIANT. Consider anti-TB therapy prior to initiation of OLUMIANT in patients with a history of latent or active TB in whom an adequate course of treatment cannot
be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.

During OLUMIANT use, monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.

Viral Reactivation
Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with OLUMIANT. If a patient develops herpes zoster, interrupt OLUMIANT treatment until the episode resolves.

The impact of OLUMIANT on chronic viral hepatitis reactivation is unknown. Patients with evidence of active hepatitis B or C infection were excluded from clinical trials. In clinical trials in patients with rheumatoid arthritis, patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA were permitted to enroll. Patients with positive hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were permitted to enroll; such patients should be monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, consult with a hepatologist. Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy with OLUMIANT.

5.2 Mortality
In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients treated with the JAK inhibitor compared with TNF blockers. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT.

5.3 Malignancy and Lymphoproliferative Disorders
Malignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)]. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients with a known malignancy (other than successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.

Non-melanoma skin cancers
Non-melanoma skin cancers (NMSCs) have been reported in patients treated with OLUMIANT. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

5.4 Major Adverse Cardiovascular Events
In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke.

5.5 Thrombosis
Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with OLUMIANT. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one
cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers.

If clinical features of DVT/PE or arterial thrombosis occur, patients should discontinue OLUMIANT and be evaluated promptly and treated appropriately. Avoid OLUMIANT in patients that may be at increased risk of thrombosis.

5.6 Gastrointestinal Perforations
Gastrointestinal perforations have been reported in clinical studies with OLUMIANT, although the role of JAK inhibition in these events is not known.

Monitor OLUMIANT-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Evaluate promptly patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.

5.7 Laboratory Abnormalities

Neutropenia – Treatment with OLUMIANT was associated with an increased incidence of neutropenia (ANC less than 1000 cells/mm³) compared to placebo.

In patients with rheumatoid arthritis, avoid initiation or interrupt OLUMIANT treatment in patients with an ANC less than 1000 cells/mm³.

In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ANC less than 1000 cells/mm³. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ANC less than 500 cells/mm³.

Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ANC [see Dosage and Administration (2.1, 2.4) and Adverse Reactions (6.1)].

Lymphopenia – ALC less than 500 cells/mm³ were reported in OLUMIANT clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with OLUMIANT, but not placebo.

In patients with rheumatoid arthritis, avoid initiation or interrupt OLUMIANT treatment in patients with an ALC less than 500 cells/mm³.

In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ALC less than 200 cells/mm³. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ANC less than 200 cells/mm³.

Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ALC [see Dosage and Administration (2.1, 2.4)].

Anemia – Decreases in hemoglobin levels to less than 8 g/dL were reported in OLUMIANT clinical trials. In patients with rheumatoid arthritis, avoid initiation or interrupt OLUMIANT treatment in patients with hemoglobin less than 8 g/dL.

Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on hemoglobin levels [see Dosage and Administration (2.1, 2.4)].

In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with hemoglobin less than 8 g/dL.

Liver Enzyme Elevations – Treatment with OLUMIANT was associated with increased incidence of liver enzyme elevation compared to placebo. Increases of ALT ≥5 times the upper limit of normal (ULN) and increases of AST ≥10 times the ULN were observed in patients in OLUMIANT clinical trials. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt OLUMIANT until this diagnosis is excluded [see Adverse Reactions (6.1)].

Lipid Elevations – Treatment with OLUMIANT was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Assessment of lipid parameters should be performed approximately 12 weeks following OLUMIANT initiation in patients with rheumatoid arthritis.
arthritis [see Adverse Reactions (6.1)]. Manage patients according to clinical guidelines for the management of hyperlipidemia.

5.8 Vaccinations
Avoid use of live vaccines with OLUMIANT. Update immunizations in patients with rheumatoid arthritis prior to initiating OLUMIANT therapy in agreement with current immunization guidelines.

5.9 Hypersensitivity
Reactions such as angioedema, urticaria, and rash that may reflect drug hypersensitivity have been observed in patients receiving OLUMIANT, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue OLUMIANT while evaluating the potential causes of the reaction [see Adverse Reactions (6.2)].

6 ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Serious Infections [see Warnings and Precautions (5.1)]
- Mortality [see Warnings and Precautions (5.2)]
- Malignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3)]
- Major Adverse Cardiovascular Events [see Warnings and Precautions (5.4)]
- Thrombosis [see Warnings and Precautions (5.5)]
- Gastrointestinal Perforations [see Warnings and Precautions (5.6)]
- Laboratory Abnormalities [see Warnings and Precautions (5.7)]
- Hypersensitivity [see Warnings and Precautions (5.9)]

6.1 Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.

Adverse Reactions in Patients with Rheumatoid Arthritis
The following data include six randomized double-blind placebo-controlled studies (three Phase 2, three Phase 3) and a long-term extension study. All patients had moderately to severely active RA. Patients were randomized to placebo (1070 patients), OLUMIANT 2 mg (479 patients), or baricitinib 4 mg (997 patients).

Patients could be switched to baricitinib 4 mg from placebo or OLUMIANT 2 mg from as early as Week 12 depending on the study design. All patients initially randomized to placebo were switched to baricitinib 4 mg by Week 24.

During the 16-week treatment period, adverse events leading to discontinuation of treatment were reported by 35 patients (11.4 per 100 patient-years) treated with placebo, 17 patients (12.1 per 100 patient-years) with OLUMIANT 2 mg, and 40 patients (13.4 per 100 patient-years) treated with baricitinib 4 mg.

During 0 to 52-week exposure, adverse events leading to discontinuation of treatment were reported by 31 patients (9.2 per 100 patient-years) with OLUMIANT 2 mg, and 92 patients (10.2 per 100 patient-years) treated with baricitinib 4 mg.

Overall Infections – During the 16-week treatment period, infections were reported by 253 patients (82.1 per 100 patient-years) treated with placebo, 139 patients (99.1 per 100 patient-years) treated with OLUMIANT 2 mg, and 298 patients (100.1 per 100 patient-years) treated with baricitinib 4 mg.

During 0 to 52-week exposure, infections were reported by 200 patients (59.6 per 100 patients-years) treated with OLUMIANT 2 mg, and 500 patients (55.3 per 100 patient-years) treated with baricitinib 4 mg.

In the 0 to 52-week exposure population, the most commonly reported infections with OLUMIANT were viral upper respiratory tract infection, upper respiratory tract infection, urinary tract infection, and bronchitis.

Serious Infections – During the 16-week treatment period, serious infections were reported in 13 patients (4.2 per 100 patient-years) treated with placebo, 5 patients (3.6 events per 100 patient-years) treated with OLUMIANT 2 mg, and 11 patients (3.7 per 100 patient-years) treated with baricitinib 4 mg.

During 0 to 52-week exposure, serious infections were reported in 14 patients (4.2 events per 100 patient-years) treated with OLUMIANT 2 mg and 32 patients (3.5 per 100 patient-years) treated with baricitinib 4 mg.
In the 0 to 52-week exposure population, the most commonly reported serious infections with OLUMIANT were pneumonia, herpes zoster, and urinary tract infection [see Warnings and Precautions (5.1)].

Tuberculosis – During the 16-week treatment period, no events of tuberculosis were reported.

During 0 to 52-week exposure, events of tuberculosis were reported in 0 patients treated with OLUMIANT 2 mg and 1 patient (0.1 per 100 patient-years) treated with baricitinib 4 mg [see Warnings and Precautions (5.1)].

Cases of disseminated tuberculosis were also reported.

Opportunistic Infections (excluding tuberculosis) – During the 16-week treatment period, opportunistic infections were reported in 2 patients (0.6 per 100 patient-years) treated with placebo, 0 patients treated with OLUMIANT 2 mg and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4 mg. During 0 to 52-week exposure, opportunistic infections were reported in 1 patient (0.3 per 100 patient-years) treated with OLUMIANT 2 mg and 5 patients (0.6 per 100 patient-years) treated with baricitinib 4 mg [see Warnings and Precautions (5.1)].

Malignancies
During the 16-week treatment period, malignancies excluding non-melanoma skin cancers (NMSC) were reported in 0 patients treated with placebo, 1 patient (0.7 per 100 patient-years) treated with OLUMIANT 2 mg, and 1 patient (0.3 per 100 patient-years) treated with baricitinib 4 mg.

During the 0 to 52-week treatment period, malignancies excluding NMSC were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 6 patients (0.7 per 100 patient-years) treated with baricitinib 4 mg [see Warnings and Precautions (5.3)].

Thrombosis
Venous Thrombosis – During the 16-week treatment period, venous thromboses (deep vein thrombosis or pulmonary embolism) were reported in 0 patients treated with placebo, 0 patients treated with OLUMIANT 2 mg, and 5 patients (1.7 per 100 patient-years) treated with baricitinib 4 mg. During the 0 to 52-week treatment period, venous thromboses were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 7 patients (0.8 per 100 patient-years) treated with baricitinib 4 mg.

Arterial Thrombosis – During the 16-week treatment period, arterial thromboses were reported in 1 patient treated with placebo (0.3 per 100 patient-years), 2 patients (1.4 per 100 patient-years) treated with OLUMIANT 2 mg, and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4 mg. During the 0 to 52-week treatment period, arterial thromboses were reported in 3 patients (0.9 per 100 patient-years) treated with OLUMIANT 2 mg and 3 patients (0.3 per 100 patient-years) treated with baricitinib 4 mg.

Laboratory Abnormalities
Neutropenia – During the 16-week treatment period, neutrophil counts below 1000 cells/mm³ occurred in 0% of patients treated with placebo, 0.6% of patients treated with OLUMIANT 2 mg, and 0.3% of patients treated with baricitinib 4 mg. There were no neutrophil counts below 500 cells/mm³ observed in any treatment group [see Warnings and Precautions (5.1, 5.7)].

Platelet Elevations – During the 16-week treatment period, increases in platelet counts above 600,000 cells/mm³ occurred in 1.1% of patients treated with placebo, 1.1% of patients treated with OLUMIANT 2 mg, and 2.0% of patients treated with baricitinib 4 mg. Mean platelet count increased by 3000 cells/mm³ at 16 weeks in patients treated with placebo, by 15,000 cells/mm³ at 16 weeks in patients treated with OLUMIANT 2 mg and by 23,000 cells/mm³ in patients treated with baricitinib 4 mg.

Liver Enzyme Elevations – Events of increases in liver enzymes ≥3 times the ULN were observed in patients treated with OLUMIANT [see Warnings and Precautions (5.7)].

- During the 16-week treatment period, ALT elevations ≥3 times the ULN occurred in 1.0% of patients treated with placebo, 1.7% of patients treated with OLUMIANT 2 mg, and 1.4% of patients treated with baricitinib 4 mg.
- During the 16-week treatment period, AST elevations ≥3 times the ULN occurred in 0.8% of patients treated with placebo, 1.3% of patients treated with OLUMIANT 2 mg, and 0.8% of patients treated with baricitinib 4 mg.
- In a phase 3 study of DMARD naive patients, during the 24-week treatment period, ALT and AST elevations ≥3 times the ULN occurred in 1.9% and 0% of patients treated with methotrexate monotherapy, 1.9% and
1.3% of patients treated with baricitinib 4 mg monotherapy, and 4.7% and 1.9% of patients treated with baricitinib 4 mg plus methotrexate.

**Lipid Elevations** – In controlled clinical trials, OLUMIANT treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and remained stable thereafter. During the 12-week treatment period, changes in lipid parameters are summarized below:

- Mean LDL cholesterol increased by 8 mg/dL in patients treated with OLUMIANT 2 mg and by 14 mg/dL in patients treated with baricitinib 4 mg.
- Mean HDL cholesterol increased by 7 mg/dL in patients treated with OLUMIANT 2 mg and by 9 mg/dL in patients treated with baricitinib 4 mg.
- The mean LDL/HDL ratio remained stable.
- Mean triglycerides increased by 7 mg/dL in patients treated with OLUMIANT 2 mg and by 15 mg/dL in patients treated with baricitinib 4 mg.

[See Warnings and Precautions (5.7)].

**Creatine Phosphokinase (CPK)** – OLUMIANT treatment was associated with increases in CPK within one week of starting OLUMIANT and plateauing after 8 to 12 weeks. At 16 weeks, the mean change in CPK for OLUMIANT 2 mg and baricitinib 4 mg was 37 IU/L and 52 IU/L, respectively.

**Creatinine** – In controlled clinical trials, dose-related increases in serum creatinine were observed with OLUMIANT treatment. At 52 weeks, the mean increase in serum creatinine was less than 0.1 mg/dL with baricitinib 4 mg. The clinical significance of the observed serum creatinine increases is unknown.

**Other Adverse Reactions**

Other adverse reactions are summarized in Table 7.

**Table 7: Adverse Reactions Occurring in Greater Than or Equal to 1% of OLUMIANT 2 mg and Baricitinib 4 mg Treated Patients in Placebo-Controlled Trials for Rheumatoid Arthritis**

<table>
<thead>
<tr>
<th>Events</th>
<th>Placebo n=1070 (%)</th>
<th>OLUMIANT 2 mg n=479 (%)</th>
<th>Baricitinib 4 mg n=997 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper respiratory tract infections</td>
<td>11.7</td>
<td>16.3</td>
<td>14.7</td>
</tr>
<tr>
<td>Nausea</td>
<td>1.6</td>
<td>2.7</td>
<td>2.8</td>
</tr>
<tr>
<td>Herpes simplex</td>
<td>0.7</td>
<td>0.8</td>
<td>1.8</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>0.4</td>
<td>1.0</td>
<td>1.4</td>
</tr>
</tbody>
</table>

- Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.
- Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.

Additional adverse drug reactions occurring in fewer than 1% of patients: acne.

**Adverse Reactions in Patients with COVID-19**

The safety of OLUMIANT was evaluated in two randomized, double-blind, placebo-controlled clinical trials of hospitalized adults with COVID-19 for up to 29 days, in which 1307 patients received at least one dose of OLUMIANT 4 mg once daily, and 1310 patients received placebo, for up to 14 days or until hospital discharge, whichever occurred first. In these studies, prophylaxis for venous thromboembolic event (VTEs) was recommended or required for all patients unless a major contraindication was noted.

Overall, the safety profile observed in patients with COVID-19 treated with OLUMIANT was consistent with the safety profile in patients with rheumatoid arthritis.

**Overall Infections** – During the first 29 days of the randomized clinical trials, infections were reported in 194 patients (14.8%) treated with OLUMIANT 4 mg and by 219 patients (16.7%) treated with placebo. The most commonly reported infection with OLUMIANT was pneumonia (3.1%).

Reference ID: 4981738
Serious Infections – During the first 29 days of the randomized clinical trials, serious infections were reported in 98 patients (7.5%) treated with OLUMIANT 4 mg and 120 patients (9.2%) treated with placebo. The most commonly reported serious infections with OLUMIANT were COVID-19 pneumonia (2.1%) and septic shock (2.1%).

Opportunistic Infections – During the first 29 days of the randomized clinical trials, opportunistic infections were reported in 12 patients (0.9%) treated with OLUMIANT 4 mg and 14 patients (1.1%) treated with placebo. Tuberculosis was reported in 1 patient (0.1%) treated with OLUMIANT 4 mg and 0 patients treated with placebo.

Venous Thrombosis Events - During the first 29 days of the randomized clinical trials, pulmonary embolism was reported in 20 patients (1.5%) treated with OLUMIANT 4 mg and 11 patients (0.8%) treated with placebo. Deep Vein Thrombosis was reported in 20 patients (1.5%) treated with OLUMIANT 4 mg and 18 patients (1.4%) treated with placebo.

Adverse drug reactions in greater than or equal to 1% of patients in trials for COVID-19 are summarized in Table 8.

Table 8: Adverse Reactions That Occurred in Greater Than or Equal to 1% of Patients Treated with OLUMIANT 4 mg Treated Patients During the First 29 Days in Placebo-Controlled Trials for COVID-19

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>OLUMIANT 4 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 1310 n (%)</td>
<td>N = 1307 n (%)</td>
</tr>
<tr>
<td>ALT ≥3 x ULNa</td>
<td>201 (16.0)</td>
<td>230 (18.1)</td>
</tr>
<tr>
<td>AST ≥3 x ULNa</td>
<td>117 (9.4)</td>
<td>149 (11.8)</td>
</tr>
<tr>
<td>Thrombocytosis &gt;600,000 cells/mm³a</td>
<td>34 (4.6)</td>
<td>59 (7.9)</td>
</tr>
<tr>
<td>Creatine phosphokinase (CPK) &gt;5 x ULNa,b</td>
<td>38 (4.7)</td>
<td>36 (4.5)</td>
</tr>
<tr>
<td>Neutropenia &lt;1000 cells/mm³a</td>
<td>22 (1.8)</td>
<td>26 (2.2)</td>
</tr>
<tr>
<td>Deep vein thrombosis</td>
<td>18 (1.4)</td>
<td>20 (1.5)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>11 (0.8)</td>
<td>20 (1.5)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>13 (1.0)</td>
<td>19 (1.5)</td>
</tr>
</tbody>
</table>

a As assessed by measured values within the clinical trial database. Frequencies are based on shifts from pre-treatment to post-treatment (with number at risk as the denominator), except for ALT and AST for which frequencies are based on observed elevation during treatment.

b Creatine phosphokinase frequencies presented in the table were available for a single trial (COVID II) in patients with COVID-19 and do not represent integrated data.

6.2 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of OLUMIANT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Drug hypersensitivity (events such as rash, urticaria, and angioedema have been observed) [see Warnings and Precautions (5.9)].

7 DRUG INTERACTIONS
7.1 Strong OAT3 Inhibitors
Baricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid) [see Dosage and Administration (2.2, 2.3) and Clinical Pharmacology (12.3)].

7.2 Other JAK Inhibitors or Biologic DMARDs
OLUMIANT has not been studied in combination with other JAK inhibitors or with biologic DMARDs [see Indications and Usage (1.1, 1.2)].

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
The limited human data on use of OLUMIANT in pregnant women are not sufficient to inform a drug-associated risk for major birth defects or miscarriage. In animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than approximately 15 and 60 times the maximum recommended human dose (MRHD) of 4 mg/day, respectively, resulted in reduced fetal body weights, increased embryolethality (rabbits...
only), and dose-related increases in skeletal malformations. No developmental toxicity was observed in pregnant rats and rabbits treated with oral baricitinib during organogenesis at approximately 3 and 9 times the exposure at the MRHD, respectively. In a pre- and postnatal development study in pregnant female rats, oral baricitinib administration at exposures approximately 30 times the MRHD resulted in reduction in pup viability (increased incidence of stillborn pups and early neonatal deaths), decreased fetal birth weight, reduced fetal body weight gain, decreased cytotoxic T cells on post-natal day (PND) 35 with evidence of recovery by PND 65, and developmental delays that might be attributable to decreased body weight gain. No developmental toxicity was observed at an exposure approximately 6 times the exposure at the MRHD [see Animal Data].

The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

In an embryofetal development study in pregnant rats, dosed orally during the period of organogenesis from gestation days 6 to 17, baricitinib was teratogenic (skeletal malformations that consisted of bent limb bones and rib anomalies) at exposures equal to or greater than approximately 15 times the MRHD (on an AUC basis at maternal oral doses of 10 mg/kg/day and higher). No developmental toxicity was observed in rats at an exposure approximately 3 times the MRHD (on an AUC basis at a maternal oral dose of 2 mg/kg/day).

In an embryofetal development study in pregnant rabbits, dosed orally during the period of organogenesis from gestation days 7 to 20, embryolethality, decreased fetal body weights, and skeletal malformations (rib anomalies) were observed in the presence of maternal toxicity at an exposure approximately 60 times the MRHD (on an AUC basis at a maternal oral dose of 30 mg/kg/day). Embryolethality consisted of increased post-implantation loss that was due to elevated incidences of both early and late resorptions. No developmental toxicity was observed in rabbits at an exposure approximately 9 times the MRHD (on an AUC basis at a maternal oral dose of 10 mg/kg/day).

In a pre- and postnatal development study in pregnant female rats dosed orally from gestation day 6 through lactation day 20, adverse findings observed in pups included decreased survival from birth to postnatal day 4 (due to increased stillbirths and early neonatal deaths), decreased birth weight, decreased body weight gain during the pre-weaning phase, increased incidence of malrotated forelimbs during the pre-weaning phase, and decreased cytotoxic T cells on PND 35 with recovery by PND 65 at exposures approximately 30 times the MRHD (on an AUC basis at a maternal oral dose of 25 mg/kg/day). Developmental delays (that may be secondary to decreased body weight gain) were observed in males and females at exposures approximately 30 times the MRHD (on an AUC basis at a maternal oral dose of 25 mg/kg/day). These findings included decreased forelimb and hindlimb grip strengths, and delayed mean age of sexual maturity. No developmental toxicity was observed in rats at an exposure approximately 6 times the MRHD (on an AUC basis at a maternal oral dose of 5 mg/kg/day).

8.2 Lactation

Risk Summary

No information is available on the presence of OLUMIANT in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Baricitinib is present in the milk of lactating rats. Due to species-specific differences in lactation physiology, the clinical relevance of these data are not clear. Because of the potential for serious adverse reactions in nursing infants, advise an OLUMIANT-treated woman with rheumatoid arthritis not to breastfeed.

Data

A single oral dose of 25 mg/kg radiolabeled baricitinib was administered to lactating female Sprague-Dawley rats on post-partum day 13. Drug exposure was approximately 45-fold greater in milk than in plasma based on AUC_{0-44} values.

8.4 Pediatric Use

The safety and effectiveness of OLUMIANT in pediatric patients have not been established.

8.5 Geriatric Use

Of the 3100 patients treated in the rheumatoid arthritis clinical trials, a total of 537 patients were 65 years of age and older, including 71 patients 75 years and older. Of the 2558 patients treated in the COVID-19 clinical trials, a total of 791 were 65 years of age and older, including 295 patients 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].
OLUMIANT is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosing and Administration (2.2, 2.3)].

8.6 Hepatic Impairment
No dose adjustment is necessary in patients with mild or moderate hepatic impairment.

The use of OLUMIANT has not been studied in patients with rheumatoid arthritis and severe hepatic impairment and is therefore not recommended. OLUMIANT has not been studied in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk [see Dosage and Administration (2.2, 2.3) and Clinical Pharmacology (12.3)].

8.7 Renal Impairment
Renal function was found to significantly affect baricitinib exposure.

**Rheumatoid Arthritis** - The recommended dose of OLUMIANT in patients with moderate renal impairment (estimated glomerular filtration rate (GFR) between 30 and <60 mL/min/1.73 m²) is 1 mg once daily. OLUMIANT is not recommended for use in patients with rheumatoid arthritis and severe renal impairment (estimated GFR of less than 30 mL/min/1.73 m²) [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].

**COVID-19** - The recommended dose of OLUMIANT in patients with moderate renal impairment (estimated GFR between 30 and <60 mL/min/1.73 m²) or severe renal impairment (estimated GFR between 15 and <30 mL/min/1.73 m²) is 2 mg once daily and 1 mg once daily, respectively. OLUMIANT is not recommended for use in patients who are on dialysis, have end-stage renal disease (ESRD), or with estimated GFR of <15 mL/min/1.73 m² [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].

10 OVERDOSAGE
Single doses up to 40 mg and multiple doses of up to 20 mg daily for 10 days have been administered in clinical trials without dose-limiting toxicity. Pharmacokinetic data of a single dose of 40 mg in healthy volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 24 hours.

In case of an overdose, it is recommended that the patient should be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.

11 DESCRIPTION
OLUMIANT (baricitinib) is a Janus kinase (JAK) inhibitor with the chemical name \{1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl\}acetonitrile. Baricitinib has an empirical formula of C_{16}H_{17}N_{7}O_{2}S and a molecular weight of 371.42. Baricitinib has the following structural formula:

OLUMIANT tablets contain a recessed area on each face of the tablet surface and are available for oral administration as debossed, film-coated, immediate-release tablets. The 1 mg tablet is very light pink, round, debossed with “Lilly” on one side and “1” on the other. The 2 mg tablet is light pink, oblong, debossed with “Lilly” on one side and “2” on the other. The 4 mg tablet is medium pink, round, debossed with “Lilly” on one side and “4” on the other.
Each tablet contains 1, 2, or 4 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, ferric oxide, lecithin (soya), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.

JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

12.2 Pharmacodynamics
Baricitinib inhibition of IL-6 induced STAT3 phosphorylation – Baricitinib administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1 hour after dosing, which returned to near baseline by 24 hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.

Immunoglobulins – Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with OLUMIANT, and remained stable through at least 52 weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.

C-reactive protein – In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with OLUMIANT and were maintained throughout dosing.

Cardiac Electrophysiology – At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics
Following oral administration of OLUMIANT, peak plasma concentrations are reached approximately at 1 hour. A dose-proportional increase in systemic exposure was observed in the therapeutic dose range. The pharmacokinetics of baricitinib do not change over time. Steady-state concentrations are achieved in 2 to 3 days with minimal accumulation after once-daily administration.

Absorption – The absolute bioavailability of baricitinib is approximately 80%. An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean AUC and Cmax of baricitinib by approximately 11% and 18%, respectively, and delayed the tmax by 0.5 hours. Administration with meals is not associated with a clinically relevant effect on exposure. In clinical studies, OLUMIANT was administered without regard to meals.

Distribution – After intravenous administration, the volume of distribution is 76 L, indicating distribution of baricitinib into tissues. Baricitinib is approximately 50% bound to plasma proteins and 45% bound to serum proteins. Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.

Elimination
RA: The total body clearance of baricitinib is 8.9 L/h in patients with RA. Elimination half-life in patients with rheumatoid arthritis is approximately 12 hours.

COVID-19: The total body clearance and half-life of baricitinib is 14.2 L/h and 10.8 hours, respectively, in patients with COVID-19 who are intubated and have baricitinib administered via NG or OG tube.

Metabolism – Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme. No metabolites of baricitinib were quantifiable in plasma.
Excretion – Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces. Baricitinib was excreted predominately as unchanged drug in urine (69%) and feces (15%).

Specific Populations
Effects of Body Weight, Gender, Race, and Age
Body weight, gender, race, ethnicity, and age did not have a clinically relevant effect on the PK (AUC and Cmax) of baricitinib (Figure 1). The mean effects of intrinsic factors on PK parameters (AUC and Cmax) were generally within the inter-subject PK variability of baricitinib. The inter-subject variabilities (% coefficients of variation) in AUC and Cmax of baricitinib are approximately 41% and 22%, respectively, in patients with rheumatoid arthritis. [see Use in Specific Populations (8.5)].

Patients with Renal Impairment
Baricitinib systemic exposure in AUC was increased by 1.41-, 2.22-, 4.05- and 2.41-fold for mild, moderate, severe, and ESRD (with hemodialysis) renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in Cmax were 1.16-, 1.46-, 1.40- and 0.88-fold, respectively (Figure 1) [see Use in Specific Populations (8.7)].

Patients with Hepatic Impairment
Baricitinib systemic exposure and Cmax increased by 1.19- and 1.08-fold for the moderate hepatic impairment group, respectively, compared to subjects with normal hepatic function (Figure 1) [see Use in Specific Populations (8.6)].

Figure 1: Impact of Intrinsic Factors on Baricitinib Pharmacokinetics

<table>
<thead>
<tr>
<th>Intrinsic Factor</th>
<th>PK Ratio and 90%CI</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight = 59 kg</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Weight = 100 kg</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Age = 65 years old</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Age = 75 years old</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Female</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Asian</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Black</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Hispanic</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Renal Impairment mild</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>moderate</td>
<td>AUC/Cmax</td>
<td>Half Recommended Dose</td>
</tr>
<tr>
<td>Severe</td>
<td>AUC/Cmax</td>
<td>Not Recommended</td>
</tr>
<tr>
<td>Hepatic Impairment</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>moderate</td>
<td>AUC/Cmax</td>
<td>No Adjustment</td>
</tr>
</tbody>
</table>

Ratio Relative to Reference

a Reference values for weight, age, gender, and race comparisons are 70 kg, 54 years, male, and white, respectively; reference groups for renal and hepatic impairment are subjects with normal renal and hepatic function, respectively.

b Effects of renal and hepatic impairment on baricitinib exposure were summarized from dedicated renal and hepatic impairment studies, respectively. Effects of other intrinsic factors on baricitinib exposure were summarized from population PK analysis.
The recommended dose for patients with COVID-19 and severe renal impairment (eGFR 15 - <30 mL/min/1.73m²) is 1 mg once daily. OLUMIANT is not recommended for use in patients with COVID-19 who are on dialysis, have end-stage renal disease (ESRD), or acute kidney injury (eGFR <15 mL/min/1.73m²). [see Dosage and Administration (2.5)]

Drug Interactions

Potential for Baricitinib to Influence the PK of Other Drugs

In vitro, baricitinib did not significantly inhibit or induce the activity of cytochrome P450 enzymes (CYPs 3A, 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6). In clinical pharmacology studies, there were no clinically meaningful changes in the pharmacokinetics (PK) of simvastatin, ethinyl estradiol, or levonorgestrel (CYP3A substrates) when co-administered with baricitinib.

In vitro studies suggest that baricitinib is not an inhibitor of the transporters, P-glycoprotein (Pgp) or Organic Anion Transporting Polypeptide (OATP) 1B1. In vitro data indicate baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT) 1, OCT2, OATP1B3, Breast Cancer Resistance Protein (BCRP) and Multidrug and Toxic Extrusion Protein (MATE) 1 and MATE2-K, but clinically meaningful changes in the pharmacokinetics of drugs that are substrates for these transporters are unlikely. In clinical pharmacology studies there were no clinically meaningful effects on the PK of digoxin (Pgp substrate) or methotrexate (substrate of several transporters) when co-administered with baricitinib.

Exposure changes of drugs following co-administration with baricitinib are shown in Figure 2.

Figure 2: Impact of Baricitinib on the Pharmacokinetics of Other Drugs

Potential for Other Drugs to Influence the PK of Baricitinib

In vitro studies suggest that baricitinib is a CYP3A4 substrate. In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor). There were no clinically meaningful changes in the PK of baricitinib when co-administered with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicin (CYP3A inducer).

In vitro studies suggest that baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K. In a clinical study, probenecid administration (strong OAT3 inhibitor) resulted in an approximately 2-fold increase in baricitinib AUC with no effect on Cmax and tmax [see Dosage and Administration (2.2, 2.3) and Drug Interactions (7.1)]. However, simulations with diclofenac
and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on the PK of baricitinib. In clinical pharmacology studies there was no clinically meaningful effect on the PK of baricitinib when co-administered with cyclosporine (Pgp and BCRP inhibitor). Co-administration with methotrexate (substrate of several transporters) did not have a clinically meaningful effect on the PK of baricitinib.

Exposure changes of baricitinib following co-administration with CYP inhibitors or inducers, transporter inhibitors, as well as methotrexate and the proton pump inhibitor, omeprazole, are shown in Figure 3.

**Figure 3: Impact of Other Drugs on the Pharmacokinetics of Baricitinib**

<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>PK</th>
<th>Ratio and 90% CI</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP3A Inhibitor</td>
<td>AUC</td>
<td></td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP3A/CYP2C19</td>
<td>AUC</td>
<td></td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Inhibitor Fluconazole</td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP Inducer Rifaximin</td>
<td>AUC</td>
<td></td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Probencid</td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAT3 Inhibitor</td>
<td>AUC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probenecid</td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simulated ibuprofen</td>
<td>AUC</td>
<td></td>
<td>Half Recommendation Dose</td>
</tr>
<tr>
<td></td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simulated Diclofenac</td>
<td>AUC</td>
<td></td>
<td>No Adjustment</td>
</tr>
<tr>
<td></td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>AUC</td>
<td></td>
<td>No Adjustment</td>
</tr>
<tr>
<td></td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pgp Inhibitor</td>
<td>AUC</td>
<td></td>
<td>No Adjustment</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omeprazole</td>
<td>AUC</td>
<td></td>
<td>No Adjustment</td>
</tr>
<tr>
<td></td>
<td>Cmax</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ratio Relative to Reference

\( ^a \) Values are based on simulated studies.

\( ^b \) Reference group is administration of baricitinib alone.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenic potential of baricitinib was evaluated in Sprague-Dawley rats and Tg.rasH2 mice. No evidence of tumorigenicity was observed in male or female rats that received baricitinib for 91 to 94 weeks at oral doses up to 8 or 25 mg/kg/day, respectively (approximately 9 and 40 times the MRHD on an AUC basis). No evidence of tumorigenicity was observed in Tg.rasH2 mice that received baricitinib for 26 weeks at oral doses up to 300 and 150 mg/kg/day in male and female mice, respectively.

Baricitinib tested negative in the following genotoxicity assays: the *in vitro* bacterial mutagenicity assay (Ames assay), *in vitro* chromosome aberration assay in human peripheral blood lymphocytes, and *in vivo* rat bone marrow micronucleus assay.

Fertility (achievement of pregnancy) was reduced in male and female rats that received baricitinib at oral doses of 50 and 100 mg/kg/day respectively (approximately 80 and 120 times the MRHD in males and females, respectively, on an AUC basis) based upon findings that 7 of 19 (36.8%) drug-treated females with evidence of mating were not gravid compared to 1 of 19 (5.3%) control females. It could not be determined from the study design if these findings were attributable to toxicities in one sex or both. Fertility was unaffected in male and female rats at oral doses of 15 mg/kg and 25 mg/kg, respectively (approximately 20 and 35 times the MRHD on an AUC basis). However, maintenance of pregnancy was adversely affected at these doses based upon findings of increased post-implantation losses (early resorptions) and
decreased numbers of mean viable embryos per litter. The number of viable embryos was unaffected in female rats that received baricitinib at an oral dose of 5 mg/kg/day and were mated to males that received the same dose (approximately 6 times the MRHD on an AUC basis). Reproductive performance was unaffected in male and female rats that received baricitinib at oral doses up to 50 and 100 mg/kg/day respectively (approximately 80 and 120 times the MRHD in males and females, respectively, on an AUC basis).

14 CLINICAL STUDIES
14.1 Rheumatoid Arthritis
The OLUMIANT clinical development program included two dose-ranging trials and four confirmatory phase 3 trials. Although other doses have been studied, the recommended dose of OLUMIANT is 2 mg once daily.

Dose-Ranging Studies
The dose-ranging studies I (NCT01185353) and II (NCT01469013) included a 12-week randomized comparison of baricitinib 1, 2, 4, and 8 mg versus placebo in 301 and 145 patients, respectively.

The results from the dose-ranging studies are shown in Table 9. In dose-ranging Study I, the observed ACR response was similar for baricitinib 1 and 2 mg daily and for baricitinib 4 and 8 mg daily, with the highest response for baricitinib 8 mg daily. In dose-ranging Study II, there was not a clear trend of dose response, with similar response rates for 1 mg and 4 mg and 2 mg and 8 mg.

Table 9: Proportion of Patients with ACR20 Response at Week 12 in Dose-Ranging Studies

<table>
<thead>
<tr>
<th>Dose-Ranging Study</th>
<th>Placebo</th>
<th>Baricitinib 1 mg daily</th>
<th>Baricitinib 2 mg daily</th>
<th>Baricitinib 4 mg daily</th>
<th>Baricitinib 8 mg daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (N=301)</td>
<td>41</td>
<td>57</td>
<td>54</td>
<td>75</td>
<td>78</td>
</tr>
<tr>
<td>II (N=145)</td>
<td>31</td>
<td>67</td>
<td>83</td>
<td>67</td>
<td>88</td>
</tr>
</tbody>
</table>

Confirmatory Studies
The efficacy and safety of OLUMIANT 2 mg once daily was assessed in two confirmatory phase 3 trials. These trials were randomized, double-blind, multicenter studies in patients with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR)/European League Against Rheumatism 2010 criteria. Patients over 18 years of age were eligible if at least 6 tender and 6 swollen joints were present at baseline. The two studies (Studies III and IV) evaluated OLUMIANT 2 mg and baricitinib 4 mg.

Study III (NCT01721057) was a 24-week trial in 684 patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to conventional DMARDs (cDMARDs). Patients received OLUMIANT 2 mg or 4 mg once daily or placebo added to existing background cDMARD treatment. From Week 16, non-responding patients could be rescued to receive baricitinib 4 mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12.

Study IV (NCT01721044) was a 24-week trial in 527 patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to 1 or more TNF inhibitor therapies with or without other biologic DMARDs (TNFi-IR). Patients received OLUMIANT 2 mg or baricitinib 4 mg once daily or placebo added to background cDMARD treatment. From Week 16, non-responding patients could be rescued to receive baricitinib 4 mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12.

Clinical Response
The percentages of OLUMIANT-treated patients achieving ACR20, ACR50, and ACR70 responses, and Disease Activity Score (DAS28-CRP) <2.6 in Studies III and IV are shown in Table 7.

Patients treated with OLUMIANT had higher rates of ACR response and DAS28-CRP <2.6 versus placebo-treated patients at Week 12 (Studies III and IV) (Table 10).

In Study IV, higher ACR20 response rates (Figure 4) were observed as early as 1 week with OLUMIANT 2 mg versus placebo.

In Study IV, the proportions of patients achieving DAS28-CRP <2.6 who had at least 3 active joints at the end of Week 24 were 18.2% and 10.5%, in the placebo and OLUMIANT 2 mg arms, respectively.
Table 10: Clinical Response

<table>
<thead>
<tr>
<th></th>
<th>Percent of Patients</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>cDMARD-IR</td>
<td></td>
<td>TNFi-IR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study III</td>
<td>Study III</td>
<td>Study IV</td>
<td>Study IV</td>
</tr>
<tr>
<td>Placebo + cDMARDs</td>
<td></td>
<td>Placebo + cDMARDs</td>
<td>Placebo + cDMARDs</td>
<td>Placebo + cDMARDs</td>
</tr>
<tr>
<td></td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
</tr>
<tr>
<td></td>
<td>(95% CI)b</td>
<td>(95% CI)b</td>
<td>(95% CI)b</td>
<td>(95% CI)b</td>
</tr>
<tr>
<td>N</td>
<td>228</td>
<td>229</td>
<td>176</td>
<td>174</td>
</tr>
<tr>
<td>ACR 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12 %</td>
<td>39</td>
<td>66</td>
<td>27</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>27 (18, 35)</td>
<td>27 (18, 35)</td>
<td>22 (12, 32)</td>
<td>22 (12, 32)</td>
</tr>
<tr>
<td>Week 24 %</td>
<td>42</td>
<td>61</td>
<td>27</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>19 (10, 28)</td>
<td>27 (10, 28)</td>
<td>18 (8, 27)</td>
<td>18 (8, 27)</td>
</tr>
<tr>
<td>ACR 50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12 %</td>
<td>13</td>
<td>34</td>
<td>8</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>21 (13, 28)</td>
<td>20 (12, 28)</td>
<td>12 (5, 19)</td>
<td>12 (5, 19)</td>
</tr>
<tr>
<td>Week 24 %</td>
<td>21</td>
<td>41</td>
<td>13</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>20 (12, 28)</td>
<td>13 (10, 28)</td>
<td>10 (2, 18)</td>
<td>10 (2, 18)</td>
</tr>
<tr>
<td>ACR 70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12 %</td>
<td>3</td>
<td>18</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>15 (9, 20)</td>
<td>11 (9, 20)</td>
<td>11 (5, 16)</td>
<td>11 (5, 16)</td>
</tr>
<tr>
<td>Week 24 %</td>
<td>8</td>
<td>25</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>17 (11, 24)</td>
<td>13 (10, 24)</td>
<td>10 (4, 16)</td>
<td>10 (4, 16)</td>
</tr>
<tr>
<td>DAS28-CRP&lt;2.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12 %</td>
<td>9</td>
<td>26</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>10 (10, 24)</td>
<td>10 (10, 24)</td>
<td>2 (2, 12)</td>
<td>2 (2, 12)</td>
</tr>
<tr>
<td>Week 24 %</td>
<td>11</td>
<td>31</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>13 (13, 27)</td>
<td>13 (13, 27)</td>
<td>11 (-1, 11)</td>
<td>11 (-1, 11)</td>
</tr>
</tbody>
</table>

a Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.

b 95% confidence interval for the difference (Δ) in response rate between OLUMIANT treatment and placebo (Study III, Study IV).

The effects of OLUMIANT treatment on the components of the ACR response criteria for Studies III and IV are shown in Table 11.

Table 11: Components of ACR Response at Week 12 in Studies III and IV

<table>
<thead>
<tr>
<th></th>
<th>cDMARD-IR</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study III</td>
<td>Study III</td>
<td>Study IV</td>
<td>Study IV</td>
</tr>
<tr>
<td></td>
<td>Placebo + cDMARDs</td>
<td>Placebo + cDMARDs</td>
<td>Placebo + cDMARDs</td>
<td>Placebo + cDMARDs</td>
</tr>
<tr>
<td></td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
<td>OLUMIANT 2 mg/day + cDMARDs</td>
</tr>
<tr>
<td></td>
<td>(95% CI)b</td>
<td>(95% CI)b</td>
<td>(95% CI)b</td>
<td>(95% CI)b</td>
</tr>
<tr>
<td>N</td>
<td>228</td>
<td>229</td>
<td>176</td>
<td>174</td>
</tr>
<tr>
<td>Number of Tender Joints (0-68)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>24 (15)</td>
<td>24 (14)</td>
<td>28 (16)</td>
<td>31 (16)</td>
</tr>
<tr>
<td>Week 12</td>
<td>15 (14)</td>
<td>11 (13)</td>
<td>20 (16)</td>
<td>19 (18)</td>
</tr>
<tr>
<td>Number of Swollen Joints (0-66)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>13 (7)</td>
<td>14 (9)</td>
<td>17 (11)</td>
<td>19 (12)</td>
</tr>
<tr>
<td>Week 12</td>
<td>8 (8)</td>
<td>5 (6)</td>
<td>12 (10)</td>
<td>10 (12)</td>
</tr>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
<td>---------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pain</strong></td>
<td>57 (23)</td>
<td>60 (21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>65 (19)</td>
<td>62 (22)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patient Global Assessment</strong></td>
<td>60 (21)</td>
<td>62 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>66 (19)</td>
<td>67 (19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Physician Global Assessment</strong></td>
<td>62 (17)</td>
<td>64 (17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>67 (19)</td>
<td>67 (17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Disability Index (HAQ-DI)</strong></td>
<td>1.50 (0.60)</td>
<td>1.51 (0.62)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.78 (0.57)</td>
<td>1.71 (0.55)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>hsCRP (mg/L)</strong></td>
<td>17.7 (20.4)</td>
<td>18.2 (21.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20.6 (25.3)</td>
<td>19.9 (22.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Data shown are mean (standard deviation).

* Visual analog scale: 0=best, 100=worst.

* Health Assessment Questionnaire–Disability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.

**Figure 4: Percent of Patients Achieving ACR20**

* Physical Function Response
  Improvement in physical function was measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI). Patients receiving OLUMIANT 2 mg demonstrated greater improvement from baseline in physical functioning compared to placebo at Week 24. The mean difference (95% CI) from placebo in HAQ-DI change from baseline at Week 24 was -0.24 (-0.35, -0.14) in Study III and -0.23 (-0.35, -0.12) in Study IV.

* Other Health Related Outcomes
  General health status was assessed by the Short Form health survey (SF-36). In Studies III and IV, compared to placebo, patients treated with OLUMIANT 2 mg demonstrated greater improvement from baseline in the physical component
summary (PCS) score and the physical function, role physical, bodily pain, vitality, and general health domains at Week 12, with no consistent improvements in the mental component summary (MCS) scores or the role emotional, mental health, and social functioning domains.

14.2 COVID-19
The efficacy and safety of baricitinib were assessed in 2 Phase 3, randomized, double-blind, placebo-controlled clinical trials:

• COVID I (NCT04401579), which evaluated the combination of baricitinib 4 mg + remdesivir compared to placebo + remdesivir.
• COVID II (NCT04421027), which evaluated baricitinib 4 mg compared to placebo. Patients could remain on background therapy, as defined per local guidelines. An additional exploratory sub-study in patients requiring invasive mechanical ventilation or ECMO at baseline was also conducted under this protocol and analyzed separately.

COVID I
A randomized, double-blind, placebo-controlled clinical trial (NCT04401579) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib plus remdesivir (n = 515) with placebo plus remdesivir (n = 518). Patients had to have laboratory-confirmed SARS-CoV-2 infection as well as at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, \( \text{SpO}_2 \leq 94\% \) on room air, a requirement for supplemental oxygen, or a requirement for mechanical ventilation or ECMO. Patients treated with the combination received the following regimen:

• Baricitinib 4 mg once daily (orally) for up to 14 days or until hospital discharge, whichever came first
• Remdesivir 200 mg on Day 1 and 100 mg once daily (via intravenous infusion) on subsequent days for a total treatment duration of 10 days or until hospital discharge

In this study prophylaxis for venous thromboembolic event (VTEs) was recommended for all patients unless a major contraindication was noted.

For the overall population (N = 1033 patients) at randomization, mean age was 55 years (with 30% of patients aged 65 or older); 63% of patients were male, 51% were Hispanic or Latino, 48% were White, 15% were Black or African American, and 10% were Asian; 14% did not require supplemental oxygen, 55% required supplemental oxygen, 21% required non-invasive ventilation or high-flow oxygen, and 11% required invasive mechanical ventilation or ECMO. The most common comorbidities were obesity (56%), hypertension (52%), and type 2 diabetes (37%). Demographics and disease characteristics were balanced across the combination group and the placebo group.

The primary endpoint, for the intent to treat population, was time to recovery within 29 days after randomization. Recovery was defined as being discharged from the hospital without limitations on activities, being discharged from the hospital with limitations on activities and/or requiring home oxygen or hospitalized but not requiring supplemental oxygen and no longer requiring medical care. The key secondary endpoint was clinical status on Day 15 assessed on an 8-point ordinal scale (OS) consisting of the following categories:

1. Not hospitalized, no limitations on activities [OS-1];
2. Not hospitalized, limitation on activities and/or requiring home oxygen [OS-2];
3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care [OS-3];
4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) [OS 4];
5. Hospitalized, requiring supplemental oxygen [OS 5];
6. Hospitalized, on non-invasive ventilation or high-flow oxygen devices [OS 6];
7. Hospitalized, on invasive mechanical ventilation or ECMO [OS 7]; and
8. Death [OS 8]

For the overall population, the median time to recovery (defined as discharged from hospital or hospitalized but not requiring supplemental oxygen or ongoing medical care) was 7 days for baricitinib + remdesivir compared to 8 days for placebo + remdesivir [hazard ratio: 1.16 (95% CI 1.01, 1.33); p = 0.035].

Patients assigned to baricitinib + remdesivir were more likely to have a better clinical status (according to an 8-point ordinal scale) at Day 15 compared to patients assigned to placebo + remdesivir [odds ratio: 1.26 (95% CI 1.01, 1.57); p = 0.044].

The proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation by Day 29 was lower in baricitinib + remdesivir (23%) compared to placebo + remdesivir (28%) [odds ratio:
Patients who required non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO) at baseline needed to worsen by at least 1 point on an 8-point ordinal scale to progress.

The proportion of patients who died by Day 29 was 4.7% (24/515) for baricitinib + remdesivir compared to 7.1% (37/518) for placebo + remdesivir [Kaplan Meier estimated difference in Day 29 probability of mortality: -2.6% (95% CI: -5.8%, 0.5%); hazard ratio = 0.65 (95% CI: 0.39, 1.09)].

COVID II

A randomized, double-blind, placebo-controlled clinical trial (NCT04421027) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib 4mg once daily (n = 764) with placebo (n = 761) for 14 days or hospital discharge, whichever came first. Patients could remain on background standard of care, as defined per local guidelines, including antimalarials, antivirals, corticosteroids, and/or azithromycin. In this study prophylaxis for venous thromboembolic event (VTE) was required for all patients unless contraindicated.

The most frequently used therapies at baseline were:
- corticosteroids (79% of patients, mostly dexamethasone)
- remdesivir (19% of patients)

Patients had to have laboratory-confirmed SARS-CoV-2 infection, at least one instance of elevation in at least one inflammatory marker above the upper limit of normal according to local laboratory ranges (CRP, D-dimer, LDH, ferritin), and at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO2 <94% on room air, evidence of active COVID infection (with clinical symptoms including any of the following: fever, vomiting, diarrhea, dry cough, tachypnea defined as respiratory rate >24 breaths/min) or requirement for supplemental oxygen.

For the overall population (N = 1525 patients) at randomization, mean age was 58 years (with 33% of patients aged 65 or older); 63% of patients were male, 60% were White, 5% were Black or African American, 11% were Asian; 12% did not require supplemental oxygen (OS 4), 63% required supplemental oxygen (OS 5), 24% required non-invasive ventilation or high-flow oxygen (OS 6). The most common comorbidities were hypertension (48%), obesity (33%), and type 2 diabetes (29%). Demographics and disease characteristics were balanced across the baricitinib and placebo groups.

The primary endpoint was the proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation within the first 28-days of the study. Patients who required non-invasive ventilation/high-flow oxygen at baseline needed to worsen by at least 1 point on an 8-point OS to progress (refer to the description of COVID I for the definition of the 8-point OS). A key secondary endpoint was all-cause mortality by Day 28.

The estimated proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation was lower in patients treated with baricitinib (27.8%) compared to placebo (30.5%), but this effect was not statistically significant [odds ratio: 0.85 (95% CI 0.67, 1.08); p = 0.180].

The proportion of patients who died by Day 28 was 8.1% (62/764) for baricitinib compared to 13.3% (101/761) for placebo [estimated difference in Day 28 probability of mortality = -4.9% (95% CI: -8.0%, -1.9%); hazard ratio = 0.56 (95% CI: 0.41, 0.77)].

COVID II Exploratory Sub-Study

In a separate group of patients requiring invasive mechanical ventilation or ECMO at baseline and enrolled in an addendum to COVID II, a pre-specified exploratory analysis showed that the proportion who died by Day 28 was 39.2% (20/51) for baricitinib compared to 58.0% (29/50) for placebo [estimated difference in Day 28 risk of mortality = -18.8% (95% CI: -36.3%, 0.6%); hazard ratio = 0.54 (95% CI: 0.31, 0.96)].

16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
OLUMIANT for oral administration is available as debossed, film-coated, immediate-release tablets. Each tablet contains a recessed area on each face of the tablet surface.
16.2 Storage and Handling
Store at 20°C to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION
Advises the patient to read the FDA-approved patient labeling (Medication Guide).

Patient Counseling
Advises patients of the potential benefits and risks of OLUMIANT.

Infections
Inform patients that they may be more likely to develop infections when taking OLUMIANT. Instruct patients to tell their healthcare provider if they develop any signs or symptoms of an infection [see Warnings and Precautions (5.1)].
Advises patients that the risk of herpes zoster is increased in patients treated with OLUMIANT and some cases can be serious [see Warnings and Precautions (5.1)].

Malignancies and Lymphoproliferative Disorders
Inform patients that OLUMIANT may increase their risk of developing lymphomas and other malignancies, including of the skin. Instruct patients to inform their healthcare provider if they have ever had any type of cancer [see Warnings and Precautions (5.3)].

Major Adverse Cardiovascular Events
Inform patients that OLUMIANT may increase their risk of major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular death. Instruct all patients, especially current or past smokers or patients with other cardiovascular risk factors, to be alert for the development of signs and symptoms of cardiovascular events [see Warnings and Precautions (5.4)].

Thrombosis
Advise patients that events of DVT and PE have been reported in clinical studies with OLUMIANT. Instruct patients to tell their healthcare provider if they develop any signs or symptoms of a DVT or PE [see Warnings and Precautions (5.5)].

Laboratory Abnormalities
Inform patients that OLUMIANT may affect certain lab tests, and that blood tests are required before and during OLUMIANT treatment [see Warnings and Precautions (5.7)].

Lactation
Advise a woman not to breastfeed during treatment with OLUMIANT [see Use in Specific Populations (8.2)].

Reference ID: 4981738
What is the most important information I should know about OLUMIANT?

OLUMIANT may cause serious side effects, including:

1. Serious infections.

OLUMIANT is a medicine that affects your immune system. OLUMIANT can lower the ability of your immune system to fight infections. Some people have had serious infections while taking OLUMIANT, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.

   - Your healthcare provider should test you for TB before starting treatment for rheumatoid arthritis with OLUMIANT.
   - Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OLUMIANT.

You should not start taking OLUMIANT if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles.

Before starting OLUMIANT, tell your healthcare provider if you:

   - are being treated for an infection.
   - have an infection that does not go away or that keeps coming back.
   - have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections.
   - have TB or have been in close contact with someone with TB.
   - have had hepatitis B or C.
   - live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OLUMIANT. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.

   - think you have an infection or have symptoms of an infection such as:
     - fever, sweating, or chills
     - muscle aches
     - cough
     - shortness of breath
     - blood in your phlegm
     - weight loss
     - warm, red, or painful skin or sores on your body
     - diarrhea or stomach pain
     - burning when you urinate or urinating more often than normal
     - feeling tired

After starting OLUMIANT, call your healthcare provider right away if you have any symptoms of an infection. OLUMIANT can make you more likely to get infections or, make worse any infection that you have.

2. Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors.

OLUMIANT is a JAK inhibitor medicine.


OLUMIANT may increase your risk of certain cancers by changing the way your immune system works.

   - Lymphoma and other cancers including skin cancers can happen in people taking OLUMIANT. People taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker. Tell your healthcare provider if you have ever had any type of cancer.

4. Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors, especially if you are a current or past smoker.

Get emergency help right away if you have any symptoms of a heart attack or stroke while taking OLUMIANT, including:

   - discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
   - severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
   - pain or discomfort in your arms, back, neck, jaw, or stomach
   - shortness of breath with or without chest discomfort
   - breaking out in a cold sweat
   - nausea or vomiting
   - feeling lightheaded
   - weakness in one part or on one side of your body
   - slurred speech


Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) and arteries (arterial thrombosis) can happen in some people taking OLUMIANT. This may be life-threatening and cause death.

Blood clots in the veins of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened...
more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors.

• Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.
• Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OLUMIANT, including: swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.

6. Tears (perforation) in the stomach or intestines.
• Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking OLUMIANT can get tears in their stomach or intestines. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
• Tell your healthcare provider right away if you have fever and stomach-area pain that does not go away, and a change in your bowel habits.

7. Changes in certain laboratory test results.
Your healthcare provider should do blood tests before you start taking OLUMIANT and while you take OLUMIANT to check for the following:
• low lymphocyte counts. Lymphocytes are white blood cells that help the body fight off infections.
• low neutrophil counts. Neutrophils are white blood cells that help the body fight off infections.
• low red blood cell counts. This may mean that you have anemia, which may make you feel weak and tired.
Your healthcare provider should routinely check certain liver tests.
You should not receive OLUMIANT if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver tests are too high.
Your healthcare provider may stop your OLUMIANT treatment for a period of time if needed because of changes in these blood test results.
You may also have changes in other laboratory tests, such as your blood cholesterol levels. If you are being treated for rheumatoid arthritis, your healthcare provider should do blood tests to check your cholesterol levels approximately 12 weeks after you start taking OLUMIANT, and as needed after that. Normal cholesterol levels are important to good heart health.

Symptoms such as rash, swelling of your lips, tongue, or throat, or hives (raised, red patches of skin that are often very itchy) that may mean you are having an allergic reaction have been seen in people taking OLUMIANT. Some of these reactions were serious. If any of these symptoms occur while you are taking OLUMIANT, stop taking OLUMIANT and call your healthcare provider right away.
See “What are the possible side effects of OLUMIANT?” for more information about side effects.

What is OLUMIANT?
• OLUMIANT is a prescription medicine used to treat:
  o adults with moderately to severely active rheumatoid arthritis after treatment with 1 or more medicines called tumor necrosis factor (TNF) blockers have been used and did not work well enough or could not be tolerated.
  o adult patients hospitalized with coronavirus disease 2019 (COVID-19) requiring oxygen or assistance with breathing.
• It is not known if OLUMIANT is safe and effective in children.

Before taking OLUMIANT, tell your healthcare provider about all your medical conditions, including if you:
• See “What is the most important information I should know about OLUMIANT?”
• have an infection.
• are a current or past smoker.
• have had a heart attack, other heart problems or stroke.
• have kidney problems.
• have liver problems.
• have low red or white blood cell counts.
• have recently received or are scheduled to receive a vaccine. People who take OLUMIANT should not receive live vaccines.
• have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines.
• are pregnant or plan to become pregnant. It is not known if OLUMIANT will harm an unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if OLUMIANT passes into your breast milk. You and your healthcare provider should decide if you will take OLUMIANT or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. OLUMIANT and other medicines may affect each other causing side effects.
Especially tell your healthcare provider if you take:
• a medicine called probenecid.
• any other medicines to treat your rheumatoid arthritis. For example, you should not take tocilizumab (Actemra®), etanercept (Enbrel®), adalimumab (Humira®), infliximab (Remicade®), rituximab (Rituxan®), abatacept (Orencia®), anakinra (Kineret®), certolizumab pegol (Cimzia®), golimumab (Simponi®), tofacitinib (Xeljanz®, Xeljanz XR®),
sarilumab (Kevzara®) while you are taking OLUMIANT. Taking OLUMIANT with these medicines may increase your risk of infection.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take OLUMIANT?
- Take OLUMIANT exactly as your healthcare provider tells you to take it.
- For people with rheumatoid arthritis, take OLUMIANT 1 time a day by mouth with or without food.
- For patients with COVID-19, OLUMIANT will be given to you 1 time a day by mouth with or without food, for up to 14 days or until you are discharged from the hospital (whichever comes first), as instructed by your healthcare provider.
- Talk to your healthcare provider if you cannot swallow tablets whole.

What are the possible side effects of OLUMIANT?
OLUMIANT can cause serious side effects including:

See “What is the most important information I should know about OLUMIANT?”

Common side effects of OLUMIANT include (these are not all of the possible side effects of OLUMIANT):
- upper respiratory tract infections (common cold, sinus infections)
- nausea

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store OLUMIANT?
Store OLUMIANT at room temperature between 68°F to 77°F (20°C to 25°C).

Keep OLUMIANT and all medicines out of the reach of children.

General Information about the safe and effective use of OLUMIANT.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use OLUMIANT for a condition for which it was not prescribed. Do not give OLUMIANT to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your healthcare provider or pharmacist for information about OLUMIANT that is written for health professionals.

What are the ingredients in OLUMIANT?
Active ingredient: baricitinib

Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide.

OLUMIANT is a registered trademark of Eli Lilly and Company.
Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA
Copyright © 2018, 2022, Eli Lilly and Company. All rights reserved.
For more information, call 1-800-545-5979 or go to the following website: www.olumiant.com.